New methods in genomics and chemistry technologies hold tremendous promise for impact on the process by which drugs are developed. Such impact, however, has yet to be realized, as these emerging methods have yet to be integrated into a discovery effort. Furthermore, the capabilities themselves need to be further developed before they can be used routinely in the drug discovery process. We therefore propose here to bring these capabilities together to create a new paradigm for drug discovery that integrates the disciplines of synthetic organic chemistry, cell biology, genomics and information science. While there is much activity in these individual areas, never before have they been synthesized and focused in such a way as to>create a new conceptual framework for drug discovery. The goal of this component of the overall Broad IRC program is therefore to create the capabilities necessary for an integrated 'pipeline'that can be applied to a wide range of applications and can be readily adopted by many groups in both academia and industry. Specifically, in Aim 1 we will develop new approaches to cell-based high throughput screening based on gene expression signatures and high content imaging.
In Aim 2, we will leverage the power of Diversity Oriented Synthesis (DOS) to create powerful small molecule libraries suitable for screening and subsequent optimization.
In Aim 3, we will develop novel strategies for toxicogenomics with the goal of using this information to better prioritize lead compounds for subsequent testing in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Linked Research project Grant (RL1)
Project #
5RL1CA133834-05
Application #
8097414
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Couch, Jennifer A
Project Start
2007-09-25
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$1,791,784
Indirect Cost
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Yu, Channing; Mannan, Aristotle M; Yvone, Griselda Metta et al. (2016) High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 34:419-23
Chou, Danny Hung-Chieh; Vetere, Amedeo; Choudhary, Amit et al. (2015) Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc 137:7929-34
Dan?ík, Vlado; Carrel, Hyman; Bodycombe, Nicole E et al. (2014) Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses. J Biomol Screen 19:771-81
Frumm, Stacey M; Fan, Zi Peng; Ross, Kenneth N et al. (2013) Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol 20:713-25
Schenone, Monica; Dan?ík, Vlado; Wagner, Bridget K et al. (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9:232-40
Mulrooney, Carol A; Lahr, David L; Quintin, Michael J et al. (2013) An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries. J Comput Aided Mol Des 27:455-68
Hartwell, Kimberly A; Miller, Peter G; Mukherjee, Siddhartha et al. (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 9:840-848
Gerard, Baudouin; Lee 4th, Maurice D; Dandapani, Sivaraman et al. (2013) Synthesis of stereochemically and skeletally diverse fused ring systems from functionalized C-glycosides. J Org Chem 78:5160-71
Taipale, Mikko; Krykbaeva, Irina; Whitesell, Luke et al. (2013) Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol 31:630-7
Lowe, Jason T; Lee 4th, Maurice D; Akella, Lakshmi B et al. (2012) Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J Org Chem 77:7187-211

Showing the most recent 10 out of 33 publications